Overview
Rejection hurts, but organ transplant rejection hurts worse, and CareDx wants to help. The company makes tests that monitor cellular rejection in heart and kidney transplant patients. Its FDA-approved AlloMap test measures gene expression in patients' blood samples to determine if a transplanted heart has been accepted. The company believes its tests will help reduce costs by decreasing the number of biopsies and drug therapies often used in evaluating
...
Read More transplants in patients. CareDx is also working on the development of AlloMap for kidney transplant patients, and it has other molecular (gene-based) diagnostic research programs in areas such as immunology. Founded in 1998, the company went public in 2014.
Read Less
Read More transplants in patients. CareDx is also working on the development of AlloMap for kidney transplant patients, and it has other molecular (gene-based) diagnostic research programs in areas such as immunology. Founded in 1998, the company went public in 2014.
Read Less
John W Hanna
See more contacts
Medical and Diagnostic Laboratories
,
Scientific Research and Development Services
,
Ambulatory Health Care Services
,
Health Care and Social Assistance
,
Medical laboratories
See All Industries Noncommercial research organizations
See Fewer Industries
See All Industries Noncommercial research organizations
See Fewer Industries
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
?
Modelled
?
Actual
$333.79 million
Actual
19.07%
$491
DEC
?
?
NASDAQ:CDNA
Contacts
Get in Touch with 5 Principals* and 308 Contacts
-
John W HannaPresident and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$333.79 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $38 | -$18 | -$25 |
| Net Investing Cash | -$0 | $40 | -$229 |
| Net Financing Cash | -$6 | -$30 | -$5 |
| Net Change in Cash | $32 | -$8 | -$258 |
| Cash at Beginning of Period | $83 | $90 | $349 |
| Cash at End of Period | $115 | $83 | $90 |
| Capital Expenditure | -$6 | -$9 | -$24 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $115 | $82 | $90 |
| Accounts Receivable | $65 | $51 | $66 |
| Inventories | $20 | $19 | $19 |
| Other Current Assets | $153 | $161 | $212 |
| Asset Summary | |||
| Total Current Assets | $352 | $314 | $388 |
| Tangible Fixed Assets | $58 | $65 | $70 |
| Intangible Assets | $38 | $46 | $43 |
| Total Assets | $491 | $467 | $543 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $8 | $13 | $10 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $82 | $65 | $66 |
| Liability Summary | |||
| Total Current Liabilities | $89 | $78 | $76 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $1 | $99 | $0 |
| Total Liabilities | $113 | $205 | $112 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$626 | -$678 | -$460 |
| Equity Summary | |||
| Total Equity | $378 | $261 | $431 |
| Shares Outstanding | 54,771,203 | 51,503,377 | 53,533,250 |